The European Commission has approved BridgeBio's acoramidis for life-threatening heart disorder transthyretin amyloidosis cardiomyopathy (ATTR-CM), setting up a market clash with Pfizer.

The UK approval is based on positive results from the Phase 3 ATTRibute-CM study, in which acoramidis demonstrated the most rapid benefit seen in any Phase 3 study of ATTR-CM to date - In as few ...

New guidance from health technology assessment (HTA) agency NICE backs the use of Wainzua (eplontersen) to treat stage 1 or 2 polyneuropathy in patients with ATTR, becoming the first option that ...

ATTR-PN is an incurable disorder in which the achieving of meaningful improvement remains an important clinical goal. Hereditary transthyretin amyloidosis can result in significant morbidity; in ...

Developed by US genetic diseases and cancer drug company BridgeBio Pharma (Nasdaq: BBIO), Beyonttra was licensed to Bayer to commercialize acoramidis for transthyretin amyloid cardiomyopathy (ATTR-CM) ...

Visit a quote page and your recently viewed tickers will be displayed here.

Peer ReviewDownload a summary of the editorial decision process including editorial decision letters, reviewer comments and author responses to feedback. Glioblastoma remains incurable and recurs in ...